PHILIP S. SCHEIN, M.D., F.A.C.P., M.R.C.P. (U.K.); VINCENT T. DeVITA Jr., M.D., F.A.C.P.; SUSAN HUBBARD, R.N.; BRUCE A. CHABNER, M.D., F.A.C.P.; GEORGE P. CANELLOS, M.D., F.A.C.P.; COSTAN BERARD, M.D.; ROBERT C. YOUNG, M.D., F.A.C.P.
A new combination chemotherapy program for patients with diffuse histiocytic and mixed histiocytic-lymphocytic lymphoma was designed to prevent tumor recurrence during the recovery period of each treatment cycle. A myelosuppressive phase consisting of adriamycin, cyclophosphamide, and vincristine was followed by the nonmyelosuppressive agents bleomycin and prednisone to suppress regrowth of lymphoma while allowing for a return in bone marrow function. Twelve of 25 patients (48%) with advanced, previously untreated, diffuse histiocytic lymphoma achieved a complete remission as determined by restaging 1 month after discontinuation of treatment. The median duration of complete response after completion of therapy is in excess of 1 year (range, 5 to 30 months), and no patient has relapsed. Based on previous experience, it is anticipated that the majority of these patients will achieve an extended disease-free survival for what had previously been regarded as an invariably fatal disease.
SCHEIN PS, DeVITA VT, HUBBARD S, et al. Bleomycin, Adriamycin, Cyclophosphamide, Vincristine, and Prednisone (BACOP) Combination Chemotherapy in the Treatment of Advanced Diffuse Histiocytic Lymphoma. Ann Intern Med. 1976;85:417–422. doi: 10.7326/0003-4819-85-4-417
Download citation file:
Published: Ann Intern Med. 1976;85(4):417-422.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use